Innate Pharma (IPHYF) 11.2800 $IPHYF
INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.
INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
ARIA: 7.35 (+0.45)
Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
BMY: 60.04 (+0.56)
INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
BMY: 60.04 (+0.56)
INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.
INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
ARIA: 7.35 (+0.45)
Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
BMY: 60.04 (+0.56)
INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
BMY: 60.04 (+0.56)
